

Dear Editor,

Thank you for reconsidering our manuscript. In the present rebuttal letter, we replied to the reviewer.

We are going to submit the revised manuscript.

We hope that our work is now suitable for publication in *World Journal of Oncology* in its current form.

Melissa Bersanelli on behalf of all the Coauthors

Reviewer Comments:

Reviewer #1: There is no real clinical hesitation in the Asia-Oceania region to use pazopanib in nccRCC patients, but this difference in perception should be corrected again using the EAU and AUA guideline recommendations as an example. Please revise the text in Introduction section.

We are grateful for this comment, but EAU and AUA recommendations do not provide recommendations about the drug considered in the present work, namely pazopanib. Nevertheless, we revised the text in the introduction section, providing the only clear recommendation by such international guidelines, which is that “Patients with non-cc-mRCC should be referred to a clinical trial, where appropriate.”